Novo Nordisk C-Suite lands in China: What's their big plan?

The Danish pharma giant, the developer of Semaglutide - Novo Nordisk's top executives kicked off a high-stakes visit in China. From speeding up new drug launches for diabetes and weight management, to boosting local investment and joint innovation projects, every stop points to deeper integration into China's fast-growing healthcare sector. As more multinational firms double down on China's market and innovation ecosystem, Novo Nordisk's journey reveals the huge opportunities within the country's “Healthy China” development blueprint. Watch CGTN's full report to unpack all key takeaways.


📺 Subscribe to our YouTube channel and stay updated with our latest analysis and interviews:👇
https://www.youtube.com/channel/UCgrNz-aDmcr2uuto8_DL2jg 👈

Download our APP on Apple Store (iOS): https://itunes.apple.com/us/app/cctvnews-app/id922456579?l=zh&ls=1&mt=8
Download our APP on Google Play (Android): https://play.google.com/store/apps/details?id=com.imib.cctv

For more:
https://www.cgtn.com/video

Most watched videos:
Impossible Challenge: 30 seconds to count banknotes BLINDFOLDED
https://www.youtube.com/watch?v=ZmP_Ybj-jws
Impossible Challenge: Gymnastics Boy Arat Hosseini from Iran!
https://www.youtube.com/watch?v=8sxX--U4c8w
Impossible Challenge: How to calm babies in 5 seconds?
https://www.youtube.com/watch?v=kR3q9sXM7WA